STOCK TITAN

Mainz Biomed N.V. - MYNZ STOCK NEWS

Welcome to our dedicated news page for Mainz Biomed N.V. (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mainz Biomed N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mainz Biomed N.V.'s position in the market.

Rhea-AI Summary
Mainz Biomed N.V. (MYNZ) to host HALLO DOC! event focusing on molecular genetics diagnostic solutions for early cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. and Ganzimmun are hosting an educational webinar on Early Detection of Colorectal Cancer, focusing on innovative laboratory diagnostic options for screening. The event aims to provide insights on genetic markers and advancements in screening techniques for accurate risk assessment and early detection. Attendees can earn continuing education credits from ÄK and BDH. The webinar will be held on March 20, 2024, in German language, targeting pharmacists, physicians, and healthcare professionals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces its participation at the 39th UDH Congress 2024, showcasing ColoAlert®, a cutting-edge colorectal cancer screening kit. The Company's commitment to advancing molecular genetics diagnostic solutions for early cancer detection is evident through its innovative technology and dedication to evidence-based healthcare practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
Rhea-AI Summary
Mainz Biomed partners with Trusted Health Advisors to advance FDA clinical trial for colorectal cancer screening test, aiming for market approval in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
partnership
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces participation at the Gynecology Congress in Germany to showcase ColoAlert®, an innovative diagnostic solution for colorectal cancer screening. The company aims to connect with gynecologists, key players in CRC prevention, and establish ColoAlert® as a leading tool in early cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) partners with Praxisdienst, Germany's largest online retailer, to distribute their innovative early cancer detection product ColoAlert®, enhancing healthcare delivery in Germany. The collaboration aims to provide a more comprehensive screening option for colorectal cancer, utilizing advanced technology for higher detection rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
partnership
Rhea-AI Summary
Mainz Biomed (NASDAQ: MYNZ) partners with TomaLab to launch ColoAlert® in Italy, revolutionizing colorectal cancer detection. ColoAlert® offers a highly effective at-home test for early cancer detection, improving survival rates in Italy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
partnership
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces the opening of the 'European Oncology Lab' (EOL), a physician-led facility in Saarland, Germany, offering ColoAlert® as a laboratory medical service directly to physicians and patients. This expansion aims to make early colorectal cancer (CRC) detection more accessible for the approximately 8.7 million individuals covered by private health insurance in Germany. The new revenue growth opportunity is expected to complement the company's established commercial sales channels, coinciding with Colorectal Cancer Awareness Month in March.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (MYNZ) reaffirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium to advance innovative colorectal cancer detection in Poland. The company aims to increase treatment options and survival rates through early detection. Mainz Biomed and TestDNA will be present as exhibitors and open the second day of panel discussions. The symposium gathers national Polish lecturers, scientists, and practitioners to share the latest insights in gastroenterology, hepatology, and gastrointestinal endoscopy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) reported groundbreaking results from ColoFuture and eAArly DETECT studies, expanded international commercialization of ColoAlert®, and announced a year-end summary of corporate and product development progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
Mainz Biomed N.V.

Nasdaq:MYNZ

MYNZ Rankings

MYNZ Stock Data

20.16M
14.78M
17.83%
1.14%
1.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Mainz

About MYNZ

mainz biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. we develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science.